KROS — Keros Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1664710 ·
Last close
$11.31
Market Cap
$221.95M
52W High
$22.55
52W Low
$8.98
ADV30
194,517
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 40,009,000 | — | 12,818,000 | 14,153,000 | 307,371,000 | 259,464,000 | 28,273,000 |
| Jun 2026 | 0 | — | -30,937,000 | -28,710,000 | 287,600,000 | 257,606,000 | 25,280,000 |
| Mar 2026 | 367,000 | — | -25,877,000 | -23,708,000 | 312,293,000 | 281,497,000 | 26,663,000 |
| Dec 2025 | 385,000 | — | -29,270,000 | -23,461,000 | 338,021,000 | 287,415,000 | 34,889,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,993,000
Investing CF
$-494,000
Financing CF
$-384,122,000
CapEx
$-494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.70
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-534,183,000
Inventory
—
Receivables
$2,757,000
ST Investments
—
EBIT TTM
$-101,468,000
Pretax Income TTM
$-86,097,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$40,761,000
EBITDA
$-68,677,000
Free Cash Flow
$-24,998,250
Enterprise Value
$-60,669,860
Total Cash
$259,464,000
Total Debt
$15,110,000
Shares Out
19,624,374
Trailing EPS
$-2.32
Book Value
$14.07
ROE
-12.6%
ROA
-8.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 244,061,000 | 67,569,000 | 87,014,000 | 338,021,000 | 34,889,000 | 303,132,000 | 107,505,000 |
| Dec 2024 | 3,550,000 | -209,595,000 | -187,353,000 | 615,886,000 | 44,333,000 | 571,553,000 | -160,869,000 |
| Dec 2023 | 151,000 | -167,541,000 | -152,992,000 | 370,025,000 | 37,812,000 | 332,213,000 | -124,508,000 |
| Dec 2022 | 0 | -107,709,000 | -104,679,000 | 306,781,000 | 29,358,000 | 277,423,000 | -70,062,000 |
TTM Snapshot
Revenues TTM
$15,014,000
NetIncome TTM
$-83,159,000
OpCashFlow TTM
—
Assets (Latest)
$287,600,000
Forward EPS
$-6.62
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $12.00 · call volume: 23 · put volume: 9
Expected Move to 2026-12-18:
±$2.67
(22.29%) —
implied range
$9.32 –
$14.68
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRX | Immuneering Corp | $224.08M | $3.46 | — |
| PRLD | Prelude Therapeutics Inc | $216.05M | $3.32 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $229.72M | $7.97 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $230.39M | $3.81 | — |
| LAB | STANDARD BIOTOOLS INC. | $212.95M | $0.54 | — |
News headlines (Yahoo Finance, 1h cache)
Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization
2026-11-16 21:01 · Yahoo
Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
2026-11-10 13:35 · Yahoo
Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
2026-11-05 21:45 · Yahoo
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
2026-10-22 23:04 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
2026-09-28 12:00 · Yahoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
2026-09-02 15:30 · Yahoo
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
2026-08-14 23:37 · Yahoo
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
2026-07-30 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.